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Abstract
Background: In vitro studies suggest that reducing cholesterol inhibits HIV replication. However, this effect may not 
hold in vivo, where other factors, such as cholesterol's immunomodulatory properties, may interact.
Methods: Fasting blood samples were obtained on 165 people living with HIV at baseline and after 24 weeks on highly 
active antiretroviral therapy (HAART). Participants were classified as hypocholesterolemic (HypoCHL; <150 mg/dl) or 
non-HypoCHL (>150 mg/dl) and were compared on viro-immune outcomes.
Results: At baseline, participants with HypoCHL (40%) exhibited lower CD4 (197 ± 181 vs. 295 ± 191 cells/mm3, p = 
0.02) and CD8 (823 ± 448 vs. 1194 ± 598 cells/mm3, p = 0.001) counts and were more likely to have detectable viral 
loads (OR = 3.5, p = 0.01) than non-HypoCHL controls. After HAART, participants with HypoCHL were twice as likely to 
experience a virological failure >400 copies (95% CI 1-2.6, p = 0.05) and to exhibit <200 CD4 (95% CI 1.03-2.9, p = 0.04) 
compared with non-HypoCHL. Low thymic output was related to poorer CD4 cell response in HypoCHL subjects. 
Analyses suggest a dose-response relationship with every increase of 50 mg/dl in cholesterol related to a parallel rise of 
50 CD4 cells.
Conclusions: The study implicates, for the first time, HypoCHL with impaired HAART effectiveness, including limited 
CD4 repletion by the thymus and suboptimal viral clearance.
Background
During the course of HIV disease, disturbances of lipid
metabolism have been observed long before the intro-
duction of highly active antiretroviral therapy (HAART)
and included hypocholesterolemia (HypoCHL; <150 mg/
dl) during early stages of the disease and hypertriglyceri-
demia in late phases [1-6]. However, the relationship
between lipids and HIV is complex, dynamic, and bi-
directional. For example, recent studies have described
different mechanisms by which HIV disrupts cholesterol
metabolism [7,8].
Conversely, the virus not only needs cholesterol as a
structural component of its membrane, but Gag also
attaches to cholesterol, and subsequent HIV-1 particle
production requires cholesterol-enriched microdomains
or rafts [7,8]. By removing cholesterol, researchers have
been able to inhibit in vitro HIV-induced syncytium for-
mation, reduce the buoyant density of viral particles,
interfere with co-receptor expression, and render cells
resistant to infection, thus significantly reducing viral
infectivity [7,8]. Accordingly, it has been suggested that
lipid-lowering drugs could be used to alter HIV infection
[7,8]. However, findings are inconsistent. For example,
Claxton and colleagues showed that cholesterol under
160 mg/dl is associated with increased risk of HIV infec-
tion [9].
Before reducing cholesterol, numerous factors require
consideration, particularly in people living with HIV
(PLHIV). For instance, cholesterol and lipid rafts integ-
rity are essential components for the appropriate func-
tion of the immune system and the preservation of health
[5,10-12]. Authors of this paper and others have shown
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evidence of some immune dysfunction in PLHIV with
HypoCHL [1-4,12].
Nevertheless, these evaluations predated the HAART
era, their focus was quite limited, and it is unclear
whether these findings are still relevant following the
HAART era. Moreover, considering that national guide-
lines and clinical recommendations for reducing choles-
terol are predicated on the idea that "lower is better"
understanding the effects of HypoCHL in PLHIV is piv-
otal [13-15]. What also remains uncertain is how much
cholesterol levels can be reduced before adverse out-
comes arise. Therefore, to address conflicting results and
these uncertainties, the main goal of the present study
was to assess in vivo the impact of HypoCHL on immune
status and viral loads before and after HAART.
Methods
Sampling
A gender- and racially-diverse HIV-infected population
was screened in January 2005 from the University of
Miami Miller School of Medicine clinics affiliated with
Jackson Memorial Hospital. HIV-infected participants
aged 18 to 55 years were eligible if they were starting
HAART regimens. Those who were not naive were eligi-
ble if they were without HAART for at least six months.
Patients were excluded if they were non-ambulatory or
if they had other conditions that might produce neurop-
sychiatric or immune/thymus compromise other than
HIV (e.g., central nervous system opportunistic infection,
head injury with or without loss of consciousness,
tumors, major psychiatric disease, developmental disor-
ders, cirrhosis, liver enzymes two standard deviations
above normal values, severe malnutrition, or autoim-
mune diseases). Participants were also excluded if they
had a family history of dyslipidemia or were receiving
lipid-lowering interventions.
The definition of HAART used for analyses was guided
by the published recommendations of the Panel on Anti-
retroviral Guidelines for Adults and Adolescents of 2008
[16,17].
Those expressing a willingness to participate (98%) and
providing written informed consent and a medical release
were enrolled and followed up after six months. No sig-
nificant differences in socio-demographic variables
existed between enrolled and non-enrolled participants.
The Institutional Review Board at the University of
Miami Miller School of Medicine approved the study.
Exposure: cholesterol assessment
Fasting blood samples were collected and processed
within six hours and sent to a clinical laboratory. None of
the PLHIV was acutely ill when blood was drawn. Total
cholesterol (TC), high-density lipoprotein (HDL), low-
density lipoprotein (LDL), and triglyceride (TG) levels
were measured by routine enzymatic methods (KonePro,
Konelab). HypoCHL (<150 mg/dL) was defined accord-
ing to the US National Cholesterol Education Program
guidelines [14,15].
Immunological and virological outcomes and assessment of 
HAART efficacy
The main study outcomes are the three laboratory tests
and the radiological procedure most related to HAART
response: thymus volumes, viral load, and CD4 and naive
cells (counts and percentages) [16]. The HIV viral burden
was quantified using the Amplicor HIV monitor test
(Roche Diagnostic System). The lower threshold for
detection at the time of the study was 400 copies/ml.
Virological failure was defined using two different thresh-
olds: (1) at least one RNA PCR result greater than 400
copies/ml during treatment follow up; or (2) if baseline
burden was >10,000 copies, having had a viral load
decline <0.5 log copies/ml [16,17].
The percentage and absolute numbers of T lymphocyte
subpopulations CD3+/CD4+ and CD3+/CD8+ cell counts
were determined by flow cytometry as per National Insti-
tute of Allergy and Infectious Diseases laboratory proto-
cols. "Immune success" was defined as achieving an
increase in circulating CD4+ T cells. However, we also
analyzed success by following the World Health Organi-
zation (WHO) definition. WHO defines immune success
as an increase of 50 CD4 cell counts after six weeks of
HAART [18].
The thymus size and naive cells (CD45RA+CD62L+)
were examined as complementary measures of immune
reconstitution, which may better reflect HAART
response. Flow cytometry was selected because it is fre-
quently used in HIV research, and its analysis is straight
forward. On the other hand, TCR Excision Circles
(TREC), which is considered the gold standard, is expen-
sive and requires mathematical models for its analyses.
Magnetic resonance imaging (MRI) without contrast
was used to determine thymus volume. The MRI was per-
formed using a thoracic surface coil and electrocardio-
graphic gating and consisted of the following sequences:
(1) sagittal and coronal pilots; (2) T1-weighted in-phase
axial, slice thickness 6 mm, interslice gap 1 mm, four
averages; (3) T1-weighted opposed-phase axial, slice
thickness 6 mm, interslice gap 1 mm, four averages; and
(4) T2-weighted fast spin echo axial fat-suppressed, slice
thickness 6 mm, interslice gap 1 mm, four averages.
The thymic volume was calculated using a quantitative
method to evaluate the true glandular composition of the
thymus, correcting for the degree of fatty infiltration.
Quantitative calculation of the thymic volume was per-
formed on T1-weighted in-phase axial slices by multiply-
ing the prevascular mediastinal area on each slice by a
correction factor, using fat and muscle signal intensities
(SI) to estimate the range of percent glandular composi-
tion of the thymus (0-100%):Míguez et al. Journal of the International AIDS Society 2010, 13:25
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where MA = mediastinum area, SI (fat) = maximal pixel
value of mediastinal fat, SI (M) = mean mediastinal signal
intensity, SI (muscle) = pectoralis muscle signal intensity.
The areas were then summed and multiplied by the 7 mm
geometric factor to obtain the thymic volume.
Control variables
At baseline and at the six-month follow up, each partici-
pant underwent an in-depth assessment, including a
detailed interview using standardized research question-
naires covering socio-demographics information, drug
and tobacco use habits, HIV infection-related data (i.e.,
stage of HIV infection), and complete past and present
medical and medications history. Medication use history
included previous exposure to antiretrovirals, lipid-low-
ering medications, and viral hepatitis treatment. These
questionnaires have been used in our previous studies
[19,20]. Adherence was calculated using both pharmacy
records and a standardized antiretroviral adherence
questionnaire. After visit procedures were completed, a
medical chart and pharmacy records were abstracted and
patient information was validated.
Alcohol consumption assessments included widely-
used standardized and validated brief screening question-
naires: The World Health Organization's Alcohol Use
Disorders Identification Test (AUDIT) has three ques-
tions on alcohol consumption, three questions on drink-
ing behavior and dependence, and four questions on the
consequences or problems related to drinking. The ADS
(Alcohol Dependence Scale) is a widely used research and
clinical tool that provides a quantitative measure of the
severity of alcohol dependence. Based on criteria estab-
lished by the National Institute of Alcohol Abuse and
Alcoholism and American Association guidelines, men
who reported >14 and women >7 drinks/week were
enrolled in Group 1 (hazardous drinkers), while those
who reported fewer drinks were included in Group 2
(non-hazardous drinkers).
Nutritional measures included 24-hour dietary intake,
anthropometrics, and albumin levels. Body weight and
height were measured and used to calculate body mass
index (BMI; weight in kilograms divided by height in
meters squared).
Statistical analyses
Data were analyzed using SPSS 15.0 (SPSS, Inc., Chicago,
IL, USA), and p values <0.05 were considered significant.
Both cross-sectional and longitudinal analyses were used.
Following descriptive statistical analyses, mean variables
were compared using Student's t-test and one-way analy-
sis of variance (ANOVA) procedures to determine the
covariates for inclusion in the univariate analyses and in
the multivariate model (e.g., age, race/ethnicity, educa-
tion level, stress, depression). Fisher's exact tests were
used when appropriate. Correlations among the main
variables of interest were examined with Pearson's coeffi-
cients. Chi-square, Student's t-test, ANOVA and analyses
of covariance (ANCOV A) were used to evaluate differ-
ences in lipid levels, HIV viral load, and immune parame-
t e r s  o f  i n t e r e s t  ( t h y m u s ,  l y m p h o c y t e  p h e n o t y p e ,  a n d
naive cells) between cases and controls at baseline and
after six months of receiving HAART.
These tests were also used to compare older and
younger participants (<45 years old and ≥45 years old). It
should be noted that the lower age limit in the literature
for "older" is 45 years of age, and since HIV accelerates
the process of aging, we decided to use this cut-off point.
Changes in lipid profiles between the baseline and the
six-month evaluations were assessed using Student's t-
test for paired samples. In addition, ANCOVA were used
to test if, after six months on HAART, viral load and CD4
changes were different between the HypoCHL and the
non-HypoCHL groups after controlling for age, gender,
adherence, and their baseline status. Viral load was trans-
formed to the log10 scale for modeling. An indicator vari-
able for a CD4 count of less than 200 cells/mm3 was
created for use in modeling.
Univariate analyses were used to calculate odds ratios
(OR) and 95% confidence intervals (CI). Finally, outcomes
and observed covariates that were significantly associated
with immune status in univariate analysis were then uti-
lized as covariates in a multivariate model. In addition,
potential participant predictors (i.e., gender, race/ethnic-
ity, CDC disease status, drug use, and BMI) were selected
based on their importance in the HIV literature and were
added to the model. Non-significant variables (p = 0.05)
were removed, beginning with the least significant vari-
ables, until the final full model was determined. Model
statistics included adjusted OR, 95% CI, and their corre-
sponding p values. For the final model, efficacy was esti-
mated according to the principle of intention to treat,
considering all missing values as failures.
Results
Study population characteristics
For analyses, the sample included 165 participants who
did not receive cholesterol-lowering medication and who
had baseline and six-month follow-up blood samples
drawn. The mean TC level of the sample was 173 ± 43
mg/dl (52-324 mg/dl) with HypoCHL present in 40% of
participants at baseline and 33% at week 24. Only 5% had
more than 250 mg/dl of TC. TC levels were unrelated to
TG levels and to malnutrition (see Table 1).
Table 1 displays the demographic and clinical charac-
teristics of the sample by cholesterol group. Groups were
comparable on sociodemographic variables. However,
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patients with HypoCHL were less likely to be white (95%
CI 0.0-0.48, p = 0.001) and more likely to be hazardous
alcohol users. Since we have previously shown that
liquor/spirits (e.g., rum, whisky, vodka) has more severe
adverse effects than other types of alcohol (beer or wine),
we explored the potential effect of specific alcoholic bev-
erages while controlling for age. HypoCHL individuals
were more likely to be hazardous liquor users than non-
HypoCHL youths (OR = 2.2, 95% CI 1-5.3, p = 0.05).
HIV medication use, including past and current pre-
scription regimens, and the proportion of protease inhib-
itor- versus non-nucleoside reverse transcriptase
inhibitor-containing regimens was not significantly dif-
Table 2: Baseline immune measures in HIV-infected participants with and without hypocholesterolemia
Variables Total cholesterol
<150 mg/dL
(n = 68)
Total cholesterol
>150 mg/dL
(n = 97)
p value
Total T lymphocytes cells/mm3 1234 ± 737 1505 ± 650 0.02
CD4 cells/mm3 197 ± 181 295 ± 191 0.02
CD8 cells/mm3 913.1 ± 390 1146.5 ± 580 0.001
Thymus volume cc3 8.5 ± 4.6 9.8 ± 2.0 0.4
Viral load HIV copies/mL 208,614 ± 42,369 150,441 ± 27,567 0.2
Note: Values are mean ± standard deviation. The p values represent t-tests comparing variables between individuals with and without 
hypocholesterolemia. Groups significantly differed in all lymphocyte measurements.
Table 1: Baseline sociodemographic information for HIV-infected participants with and without hypocholesterolemia
Variables Total cholesterol
<150 mg/dL
(n = 68)
Total cholesterol
>150 mg/dL
(n = 97)
Age in years 39.8 ± 7.9 41.1 ± 7.2
Men 72% 68%
Women 28% 32%
Black 65% 55%
Hispanic 33% 29%
White 0% 16%
Annual income
Less than $10,000 89% 88%
$11,000-$20,000 9% 10%
More than $20,000 2% 2%
Cigarette smoker 81% 80%
Hazardous alcohol use 64% 48%
Drug use 42% 39%
Albumin in mg/dl 4.0 ± 0.4 4.1 ± 0.5
Body mass index in kg/m2 26.2 ± 6.2 27.4 ± 6.7
Number of years diagnosed with HIV 9.7 ± 6.6 8.7 ± 5.6
Note: Values are mean ± standard deviation or percentages. The data represent descriptive statistics and comparisons of key variables 
between individuals with and without hypocholesterolemia. No significant differences in socio-demographic characteristics were found 
between groups.Míguez et al. Journal of the International AIDS Society 2010, 13:25
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ferent. The difference between the two groups in adjusted
adherence to medication was only 3%.
Important for understanding the relationship between
HypoCHL and immune response is whether the results
are moderated by overall health indices (i.e., albumin and
anthropometrics). As shown in Table 1, albumin and BMI
were comparable between groups. Also to be considered
was the effect of viral hepatitis, but the exclusion of par-
ticipants with cirrhosis or liver enzymes two standard
deviations above normal values highly reduced the likeli-
hood that patients with active hepatitis C would be
enrolled and affect the outcomes. In addition, the JMH
clinic that served as the recruitment site conducts an
annual screening for viral hepatitis among PLHIV clients.
Once positive, clients are immediately referred to treat-
ment and our treatment records had no evidence of such
events.
Baseline cholesterol and immune parameters
Immune results are displayed in Table 2 and depict men
and women in the mid-range of illness (CD4 numbers
between 150 and 500). Overall, the analyses revealed that
relative to the control group, HypoCHL subjects had sig-
nificantly less circulating total T cells and fewer CD4 (197
± 181 vs. 295 ± 191 cells/mm3, p = 0.02) and CD8 counts.
Nonetheless, 25% of PLHIV with more than 500 CD4 cell
c o u n t s  e x h i b i t e d  H yp o C H L,  i n d i c a t i n g  t h a t  i t  w a s  n o t
restricted to advanced stages of the disease.
Univariate analyses demonstrated that members of the
HypoCHL group were twice as likely to have CD4 counts
below 200 cells as those in the control group (95% CI 1.0-
4.13, p = 0.03). Analyses of immunological data in older
PLHIV revealed a significant relationship between
HypoCHL and low absolute CD8+ T cell counts (913.1 ±
390 vs. 1146.5 ± 580 cells/mm3, p = 0.003). Older partici-
pants with HypoCHL also had significantly lower per-
centages of both naive CD8+ (25 ± 8 vs. 75 ± 15) and
naive CD4+ cells (13.0 ± 2 vs. 26.5) compared with the
older non-HypoCHL subgroup. Relative to the young
group with normal values, the younger group with
HypoCHL had significantly lower CD8+ T cell counts
(826.7 ± 50 vs. 1175.5 ± 74, p = 0.002), with a tendency for
lower CD4 absolute numbers (204.6 ± 29 vs. 268.6 ± 23.5,
p = 0.06) and CD4 (p = 0.08) naive cells.
Baseline cholesterol and HIV viral loads
TC and viral load levels were significantly correlated (r =
0.3, p = 0.02). Although not statistically significant, sub-
jects with HypoCHL did not exhibit lower, but rather
higher viral loads (see Table 2). Moreover, in contrast to
results from in vitro studies, univariate analyses indicated
that participants with non-HypoCHL were more likely to
have an undetectable viral load than those with
HypoCHL (OR = 3.5, 95% CI 1.2-11, p = 0.01).
Longitudinal analyses of viral load response after 24 weeksof 
HAART
An undetectable viral load was achieved by 69 partici-
pants (42%). Sixty-six subjects (40%) had a viral load
decline >0.5 log copies/ml, but still detectable viral load at
the last visit, while the remaining participants had no
decline or declined ≤0.5 log copies/ml. It is noteworthy
that despite similar medication adherence, a significantly
greater proportion of HypoCHL participants had a viro-
logic failure compared with the control group (19% vs.
9%, p = 0.04), and they had a non-significant reduction of
32,070 HIV copies (-0.6 log). In contrast, in the non-
HypoCHL group, a significant decrease in viral load after
24 weeks (87,440 HIV copies = 1.6 log, p = 0.004) was
observed.
After controlling for age, gender, and the baseline log
viral load, an ANCOVA model showed that the six-
month log viral load of the HypoCHL group was signifi-
cantly higher (p = 0.04) by 0.93log, than the non-
HypoCHL group. Figure 1 illustrates the significantly dif-
ferent slope of change between the two groups using the
actual values. Analysis showed a strong negative correla-
tion between CD8 cell counts and viral load at week 24 (r
= 0.38, p = 0.006). After controlling for adherence, partic-
ipants without HypoCHL experienced a greater drop (p =
0.012) in mean viral loads with HAART than did partici-
pants with HypoCHL (see Figure 1).
Table 3: Multivariate analyses for CD4 below 200 cell counts
Predictors of CD4 below 200 cell counts/mm3
MODEL MULTIVARIATE RR 95% CI p Value
Hypocholesterolemia 7.7 2.1-27 0.002
Small thymus 0.07 0.06-0.8 0.03
A persistent viral load 8.6 1.0-70 0.045
Hazardous liquor use 1.6 1.0-2.3 0.053
RR represents the final Logistic regression model predicting CD4 cell counts below 200 cells/mm3 after 6 months of HAART. Significance was 
set at 0.05. Model statistics computed include adjusted OR, 95% CI, and their corresponding p values. Hypocholesterolemia, thymus, and viral 
load were set as dichotomous variables.Míguez et al. Journal of the International AIDS Society 2010, 13:25
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Longitudinal analyses of immune recovery after 24 weeks of 
HAART
After six months on HAART, PLHIV with persistent
HypoCHL exhibited significantly lower thymus volumes
(6.9 ± 4.4 vs. 10.8 ± 7 cc3, p = 0.03). Figure 2 shows that
the therapy induced a limited increase of CD4+ T cells in
the HypoCHL group compared with controls (+18 vs.
+102 cells/mm3, p = 0.001). Analysis of naive cells was
more alarming, as participants in the control group
showed increases in CD4+ T cells (+29 cell counts/mm3),
compared with values obtained from HypoCHL individu-
als who exhibited a decline (-59 cells/mm3). These
changes parallel those of thymus volumes, while controls
exhibited an increased in thymus volumes (+2.4 cc3, p =
0.09), those with HypoCHL had a significant decrease (-
2.8 cc3, p = 0.04).
Accordingly, participants with HypoCHL were twice as
likely to have <200 CD4 cell counts (OR = 1.6, 95% CI
1.03-2.88, p = 0.04) and five times less likely to achieve
more than 500 CD4 cell at six months (OR = 5.4, 95% CI
3.1-9.4, p = 0.0001) than controls. Both groups exhibited
a fall in total number of CD8+ T lymphocytes. However,
decreases were more evident in the HypoCHL group. As
a result, after six months of therapy, the HypoCHL group
exhibited significantly lower total CD8 cell counts (823 ±
448 vs. 1194 ± 598 cells/mm3, p = 0.001). Additional anal-
yses revealed that HAART-induced expansion of the
naive subset was better in participants with normal base-
line cholesterol (Figure 2).
Given the observed deleterious effects of HypoCHL, we
then examined if these effects had a threshold on immune
responses. To address this question, the HypoCHL group
was dichotomized into those with baseline cholesterol
values above (n = 40) and below the group mean (120 mg/
dl, n = 28). The outcome variable was viro-immune mea-
sures at the last visit. Groups significantly differed in viral
loads, total T cell, and CD8 counts; those with less than
120 mg/dl exhibited the worst viro-immune profile (CD3
= 1011.9 ± 110 vs. 1427 ± 109 cells/mm3, p = 0.03; CD8 =
694.5 ± 89 vs. 1110 ± 103 cells/mm3, p = 0.01; and log
viral load 2.9 ± 2.2 vs. 4.7 ± 1.2 copies, p = 0.03).
Final analyses of HAART efficacy
After adjusting for age, gender, CDC status, and other
covariates (e.g., BMI), HypoCHL was the only inde-
pendent risk factor of virological failure after six
months of HAART (RR = 1.7, 95% CI 1-2.6, p = 0.05).
In fully adjusted models (sociodemographics, baseline
CDC stage, drug use, and adherence), HypoCHL (RR =
7.7, p = 0.002), thymus volume (above or below 9,
which is the mean of the study population, RR = 0.07, p
= 0.03), hazardous liquor use (RR = 1.57, p = 0.05), and
detectable viral loads at the last visit (RR = 8.6, p =
0.04), significantly predicted CD4 below 200 cell
counts (see Table 3).
To examine a possible dose-response relationship, cho-
lesterol was converted into an ordinal variable with four
levels (100-150, 151-200, 201-250, and >251 mg/dl) and
mean CD4 counts were compared. As depicted in Figure
3, the results suggested a dose-response relationship
between TC and CD4 cell counts after HAART (p < 0.05).
Based on this analysis, every increase of 50 mg/dl in TC
was accompanied by an increase in CD4 of 50 cell counts.
Figure 1 Viral loads before and after HAART by cholesterol 
groups. Figure 1 indicates trends in viral loads between HIV positives 
with Hypocholesterolemia (n = 68) and controls (n = 97), starting at the 
visit before HAART, and extending over a six-month period, after ad-
justment for adherence. As depicted in the figure, a significant drop in 
viral load was attained in the individuals with cholesterol values above 
150 mg/dl.
Figure 2 T cell replenishment with HAART by cholesterol groups. 
Data represent mean changes in CD4 and total naive T cell counts after 
HAART in the two groups and were tested with paired-sample t-tests. 
Both CD4 and total naive subsets controls (n = 97, in the blue colors) 
exhibited a significant improvements after HAART (p = 0.001). On the 
contrary, PLHIV with HypoCHL (n = 68, orange and red), showed a re-
duction in total number of CD4 cells, and only a non-significant in-
crease in total naive cells (CD3+CD45RA+CD62L+).Míguez et al. Journal of the International AIDS Society 2010, 13:25
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Discussion
Although primarily high TC has been publicized as
unhealthy [21,22], results from this longitudinal study
indicate that low cholesterol in PLHIV may be as insalu-
brious or worse than high cholesterol. In addition, our
findings highlight the importance of cholesterol in
increasing immune resilience and maintaining thymus
function in older PLHIV.
Equally important, HypoCHL was fulfilling all the
established IARC (International Agency for Research on
Cancer) criteria to attribute morbidity to a given expo-
sure [23,24]. These are:
a. Our results were consistent with previous studies 
and highly significant (RR = 7.7, p = 0.002).
b. The data indicated a temporal relationship 
between cholesterol status and immune responses.
c. Analyses suggest a dose-response relationship.
d. Our findings demonstrate, for the first time, a 
mechanism mediating the deleterious effect of 
HypoCHL on T lymphocytes and, thus, on HAART 
effectiveness.
e. Reversibility of effects: Participants who normalized 
their cholesterol values did not exhibit the deleterious 
profile of those who demonstrated persistent 
HypoCHL.
Several biological factors may be considered to account
for an inverse relationship between cholesterol levels and
immune impairment. The deleterious effects of
HypoCHL on the thymus may explain our findings of
fewer circulating total T, CD4, and CD8 cells in these
subjects, but also Rodriguez et al [25] observed that sta-
tins blunt short-term CD4 gains with HAART. In non-
HIV infected participants, Muldoon and colleagues [26]
also observed a depletion of CD4 and less interleukin-2
(IL-2) release in response to mitogen stimulation in
HypoCHL participants.
Considering that IL-2 has been shown to prevent T cell
apoptosis, one can postulate that cholesterol's effects on
IL-2 and the thymus may explain the fewer cells observed
with HypoCHL in our participants [27,28]. Moreover, last
year, an animal study demonstrated that cholesterol mod-
ifications can affect IL-7 production, which is necessary
for thymus expansion and production of naive cells [29].
Therefore, one can postulate that HypoCHL, by affect-
ing IL-2 and IL-7, may decrease T cell production, prolif-
eration, survival, and repletion under HAART. Given the
thymus's sensitivity to metabolic changes, and the role of
cholesterol in lipid rafts, and considering that prolifera-
tion and generation of new cells is a cholesterol-demand-
ing process, our findings were not wholly unexpected.
Nevertheless, the exact mechanism(s) mediating
HypoCHL's effects on thymus size and function requires
further investigation.
Recently,  in vitro studies have revolutionized our
understanding of HIV infection by demonstrating that
HIV is dependent on cholesterol [30-34]. The virus not
only needs cholesterol as a structural component of its
membrane, but it also takes advantage of membrane lipid
rafts for the attachment and entry into the cells [30-34].
Using cell lipid rafts as a point of entry allows the virus to
exploit the high concentration of cellular receptors CD4,
CCXCR4, and CCR5 that are required for virus entry
[5,31,32]. Nonetheless, it has been argued that cholesterol
modulates HIV entry independently of its ability to pro-
mote lipid raft formation [33].
Finally, Nef-enhanced cholesterol synthesis is thought
to sustain virion assembly in lipid rafts and budding from
the membrane. By removing cholesterol, researchers have
been able to inhibit in vitro HIV-induced syncytium for-
mation and reduce the buoyant density of viral particles
and virus infectivity [35]. This has led to advocacy of cho-
lesterol-lowering interventions, as a beneficial strategy
for both preventing and treating HIV [29-33,36]. Cur-
rently, the field is confronted with contradictory and
often discouraging data in human subjects [25,37-40].
Three studies found no beneficial effects, while two other
studies demonstrated that cholesterol-lowering drugs
increased viral replication, particularly in individuals
with low cellular cholesterol [25,37-39,41].
Our study results showed that participants with
HypoCHL exhibited higher, rather than lower, viral loads.
The discrepancies between our results and those from in
vitro experiments may be related to several factors. First,
in vitro research focuses on cell membrane cholesterol,
and we only evaluated plasma levels [29-34,42]. Second,
Figure 3 CD4 counts by cholesterol. Mean CD4 cell counts of the to-
tal group were stratified by increases of 50 cell counts and plotted 
against cholesterol groups in increments of 100 mg/dl. R and p values 
were calculated by linear regression analysis. As depicted, CD4 cell 
counts increased linearly with increases in cholesterol.Míguez et al. Journal of the International AIDS Society 2010, 13:25
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in laboratory experiments, only cells that over-express
HIV co-receptors of entry have been used. Third, those
researchers utilizing experimental models cannot exam-
ine the systemic effect of such a manipulation.
Our findings are probably associated with a weaker
immune response toward the virus, as indicated by the
significant correlations between CD8 counts and choles-
terol on the one hand and the negative correlation
between CD8 and viral loads on the other. CD8 anti-HIV
activity is sufficiently well- documented, so that such fur-
ther discussion may be unnecessary [43]. It is also possi-
ble that during the acute phase of infection (in vitro
model), HypoCHL may help to contain viral replication
and then contribute to immune suppression and poor
viremic control once an individual enters the chronic
stage of infection.
Finally, both HIV and alcohol abuse have been associ-
ated with altered gut permeability and microbial translo-
cation, which are linked with immune activation, leading
to increase viral replication [44,45].
Few studies have focused on CD8+ T cells and even less
have evaluated naive CD8 cell changes. Only one other
study, in non-HIV-infected individuals, has reported the
effect of age on naive CD8 T-cell counts [46]. Our results
extend the prior publication by demonstrating that the
depletion of CD8 naive cells is significantly associated
with HypoCHL. Considering that CD8 lymphocytes, par-
ticularly naive cells, are involved in the body's response to
novel class antigens (i.e., viruses and malignant cells), our
findings offer a mechanism for explaining why respira-
tory infections and cancer may be important causes of
morbidity and mortality in the HypoCHL aging popula-
tion.
In summary, this study indicates that HypoCHL is sig-
nificantly associated with impaired viro-immune
response in participants with and without HAART. Our
findings have important clinical implications. First, our
results highlight the value of further elucidating the
impact of TC and lipid-lowering drugs on the immune
systems of PLHIV because any additional suppression
may produce harm. Second, it emphasizes the need to
further evaluate clinical guidelines regarding TC levels in
PLHIV. It also calls for caution in advocating for lipid-
lowering medications as a preventive or adjuvant therapy
against HIV.
In the HAART era, when physicians are particularly
concerned with hypercholesterolemia increasing the risks
of viral infectivity and cardiovascular disease, our data
indicate that HypoCHL is as clinically relevant. However,
some limitations of our study should be noted. First, the
study only indicates an association and cannot establish a
causal relationship. However, several factors reduce the
likelihood of our findings being due to chance: the magni-
tude of the association between HypoCHL and HAART-
blunted responses; the biological plausibility of this asso-
ciation; the temporality of the relationship; the dose-
response relationship; and the longitudinal design of the
study.
Additionally, it is important to note that the size of the
current study allows only moderate estimates of change
in the lipid profiles following HAART. Also, our results
are limited to a single cohort, followed in a clinical setting
where antiretrovirals are readily available, compliance is
high, and black patients are over-represented. Whether
the results will generalize to different populations needs
future clarification.
Even though our data reflect only the initial six months
of therapy, previous studies indicate that most HAART-
related changes occur within this time period [22]. There-
fore, larger samples with longer follow-up periods are
recommended to corroborate our findings. Finally, we did
not include intracellular measurements of cholesterol
since, in practice, clinicians measure blood levels, not
intracellular cholesterol, rendering our results of greater
applicability to clinical settings.
Conclusions
Despite these limitations, our in vivo study of how
HypoCHL affects PLHIV extends the literature in several
ways. First, to our knowledge, this is the first cohort study
of lipids in antiretroviral-treated patients that considers
thymus volumes and measurements of recent T cell out-
puts in addition to CD4 cell counts and viral load. Sec-
ond, the study design permitted us to examine the
importance of HypoCHL in HIV disease at baseline and
the biological effects of HypoCHL on HAART effective-
ness.
Finally, we were able to avoid the confounding effects of
individuals in therapy at diverse times with all partici-
pants initiating treatment at the same point. Currently,
comprehensive studies to elucidate the role of cholesterol
in health and disease are needed to help inform public
health authorities and health care providers on treatment
decisions.
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